Lab for Home 1

Boehringer Ingelheim Program on Track


In May 2015 Boehringer acquired the Pharmaxis investigational drug PXS-4728A to develop initially as a treatment for non-alcoholic steatohepatitis (NASH). During the March 2016 quarter Boehringer provided a program update confirming the planned timing for the commencement of a phase 2 clinical trial as the first quarter of 2017. The commencement of a phase 2 trial triggers the payment of a development milestone to Pharmaxis of approximately A$25 million.

Find out more about the sale to Boehringer

Find out more about NASH

Latest news on NASH

A silent liver disease epidemic As nonalcoholic steatohepatitis, or NASH, stealthily becomes a leading cause of liver transplants, drug companies are racing to develop treatments. Lisa M. Jarvis, Chemical & Engineering News, October 3, 2016

Big Pharma, Biotech Attack NASH Liver Illness From All SidesSeptember 21, 2016



Pic for Russia

Pharmaxis Announces Russian Approval For Bronchitol - Largest Market Accessed to Date

Pharmaxis is pleased to announce its drug Bronchitol® has been approved for marketing in Russia for the treatment of both paediatric and adult cystic fibrosis (CF) patients. Russia is the largest market accessed to date for Bronchitol.

In a landmark decision Bronchitol today became the first medicine to be processed under new Russian laws to provide patients access to innovative medicines.The new orphan drug legislation was announced by the Russian Ministry of Health in January 2016, and Bronchitol was designated as an orphan drug the following month.

There are approximately 7,400 CF patients on the Russian Cystic Fibrosis Registry, but it is estimated there are between 3,000 and 6,000 CF patients living in rural regions not currently included on the registry. Last year the Russian market for CF drugs to deal with mucus clearance was approximately US$29 million.  The first Russian sales of Bronchitol are expected before the end of 2016.

Read more

Read The Australian report

2016 08 24 ACS

Stopping scars before they form

Pharmaxis is collaborating on a potential new scar treatment for burns, keloids and Dupuytren contracture. Early stage research from a group including The University of Western Australia, Fiona Wood Foundation, Royal Perth Hospital Burns Unit and Pharmaxis has been presented at the prestigious American Chemical Society meeting in Philadelphia.

The team tested their molecules using a “Scar-in-a-jar” model, which mimics scar formation. In short, this technique involved culturing human fibroblasts from scar tissues in a petri dish. The cells overproduce and secrete collagen, as they would in a real injury. In the study, the researchers added LOX inhibitors to cultures from patients with Dupuytren’s, keloids and other scar tissue, and detected changes using two-photon microscopy combined with biochemical and immunohistochemical analyses.

According to Swaminathan Iyer, Ph.D. from The University of Western Australia, “The preliminary data strongly suggest that lysyl oxidase inhibition alters the collagen architecture and restores it to the normal architecture found in the skin.”

Find out more